CTXR logo

CTXR
Citius Pharmaceuticals Inc

21,537
Mkt Cap
$15.37M
Volume
197,985.00
52W High
$2.97
52W Low
$0.63
PE Ratio
-0.19
CTXR Fundamentals
Price
$0.75
Prev Close
$0.7401
Open
$0.7304
50D MA
$0.9963
Beta
1.25
Avg. Volume
1.48M
EPS (Annual)
-$3.38
P/B
0.20
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Citius Pharmaceuticals (CTXR) Surges 22% After Hours Here's Why
Citius Pharmaceuticals shares jumped 22.12% after hours following the commercial launch of its LYMPHIR therapy and a fiscal 2025 business update.read more...
Benzinga·1mo ago
News Placeholder
More News
News Placeholder
Citius Pharmaceuticals Inc. Full Year Loss Decreases
(RTTNews) - Citius Pharmaceuticals Inc. (CTXR.OB) released Loss for full year of -$37.43 million...
Nasdaq News: Markets·1mo ago
News Placeholder
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update PR Newswire...
PR Newswire·1mo ago
News Placeholder
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business...
PR Newswire·1mo ago
News Placeholder
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules Citius Oncology Announces Closing of $18 Million...
PR Newswire·2mo ago
News Placeholder
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules Citius Oncology Announces $18 Million Concurrent Registered...
PR Newswire·2mo ago
News Placeholder
Citius Oncology Expands LYMPHIR Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
Citius Oncology Expands LYMPHIR Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim Citius Oncology Expands LYMPHIR Distribution to Turkey and Middle East...
PR Newswire·2mo ago
News Placeholder
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) Citius Oncology Announces U.S. Commercial Launch of LYMPHIR, a Novel...
PR Newswire·2mo ago
News Placeholder
Citius Oncology to Advance Commercial Launch of LYMPHIR with Verix AI Integration
Citius Oncology to Advance Commercial Launch of LYMPHIR with Verix AI Integration Citius Oncology to Advance Commercial Launch of LYMPHIR with Verix AI Integration PR Newswire CRANFORD, N.J., Nov...
PR Newswire·2mo ago
News Placeholder
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules Citius Pharmaceuticals Announces the Closing of Registered Direct...
PR Newswire·3mo ago
<
1
2
...
>

Latest CTXR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.